norfluoxetine has been researched along with Epilepsy in 3 studies
norfluoxetine: metabolite of fluoxetine; RN given refers to parent cpd without isomeric designation
Epilepsy: A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fluoxetine, an antidepressant and inhibitor of serotonin reuptake, was evaluated as an anticonvulsant in genetically epilepsy-prone rats (GEPRs) because seizure predisposition in GEPRs is partially dependent on deficits in brain serotonin." | 7.68 | Effects of fluoxetine on convulsions and on brain serotonin as detected by microdialysis in genetically epilepsy-prone rats. ( Burger, RL; Dailey, JW; Jobe, PC; Mishra, PK; Yan, QS, 1992) |
| " In this study the anticonvulsant actions of norfluoxetine and fluoxetine were studied and compared to those of phenytoin and clonazepam in pentylenetetrazol-induced mouse epilepsy models." | 3.73 | Norfluoxetine and fluoxetine have similar anticonvulsant and Ca2+ channel blocking potencies. ( Harasztosi, C; Kecskeméti, V; Nánási, PP; Pál, B; Riba, P; Rusznák, Z; Szûcs, G; Wagner, R, 2005) |
| "Fluoxetine, an antidepressant and inhibitor of serotonin reuptake, was evaluated as an anticonvulsant in genetically epilepsy-prone rats (GEPRs) because seizure predisposition in GEPRs is partially dependent on deficits in brain serotonin." | 3.68 | Effects of fluoxetine on convulsions and on brain serotonin as detected by microdialysis in genetically epilepsy-prone rats. ( Burger, RL; Dailey, JW; Jobe, PC; Mishra, PK; Yan, QS, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vivier, D | 1 |
| Bennis, K | 1 |
| Lesage, F | 1 |
| Ducki, S | 1 |
| Kecskeméti, V | 1 |
| Rusznák, Z | 1 |
| Riba, P | 1 |
| Pál, B | 1 |
| Wagner, R | 1 |
| Harasztosi, C | 1 |
| Nánási, PP | 1 |
| Szûcs, G | 1 |
| Dailey, JW | 1 |
| Yan, QS | 1 |
| Mishra, PK | 1 |
| Burger, RL | 1 |
| Jobe, PC | 1 |
1 review available for norfluoxetine and Epilepsy
| Article | Year |
|---|---|
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Struc | 2016 |
2 other studies available for norfluoxetine and Epilepsy
| Article | Year |
|---|---|
Norfluoxetine and fluoxetine have similar anticonvulsant and Ca2+ channel blocking potencies.
Topics: Animals; Anticonvulsants; Barium; Calcium; Calcium Channel Blockers; Calcium Channels; Calcium Signa | 2005 |
Effects of fluoxetine on convulsions and on brain serotonin as detected by microdialysis in genetically epilepsy-prone rats.
Topics: Animals; Brain; Dialysis; Epilepsy; Female; Fluoxetine; Male; Rats; Seizures; Serotonin; Thalamus | 1992 |